Compare PSTV & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSTV | RFL |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 54.4M |
| IPO Year | N/A | N/A |
| Metric | PSTV | RFL |
|---|---|---|
| Price | $0.57 | $1.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 182.7K |
| Earning Date | 10-30-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,258,000.00 | $1,029,000.00 |
| Revenue This Year | $28.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.63 |
| 52 Week Low | $0.16 | $1.15 |
| 52 Week High | $2.31 | $3.19 |
| Indicator | PSTV | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 40.44 |
| Support Level | $0.54 | $1.21 |
| Resistance Level | $0.60 | $1.35 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 14.39 | 6.67 |
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.